Sanofi strikes autoimmune drug deal for up to $1.9B
Sanofi (NASDAQ:SNY) has agreed to acquire an immunology drug from clinical-stage biopharmaceutical company Dren Bio for up to ...
Sanofi Agrees US Autoimmune Drug Deal for Up to $1.9 Billion
Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...
EconoTimes2h
Sanofi to Acquire Dren Bio’s Autoimmune Drug DR-0201 in $1.9B Deal
Sanofi (NASDAQ:SNY) has struck a major deal to acquire Dren Bios autoimmune disease treatment, DR-0201, reinforcing its expansion in the biopharmaceutical sector. The French healthcare giant announced ...
Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion
Sanofi said it would acquire Bispecific Myeloid Cell Engager, an autoimmune disease treatment, from Dren Bio, for up to $1.9 billion.
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...
CABLIVI Market Reports Positive Growth - Strong Momentum Expected To Continue Delveinsight
Developed by Sanofi, CABLIVI is the first FDA-approved nanobody therapy for this condition. Increasing awareness, improved diagnostic rates, ...
Sanofi Offers Rs 117 Final Dividend: Will It Trigger Bullish Momentum Before 25th April?
Sanofi Indias shares ended Wednesdays trading session on the NSE 0.41% down at Rs 5,600 with a market value of Rs 12.90KCr, ...